Compare Lamb Weston Holdings Inc (LW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Tango Therapeutics Inc. — how do they compare? Lamb Weston Holdings Inc trades at $53.22 (market cap $7.16B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Lamb Weston Holdings Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Tango Therapeutics Inc. for 0 Days on average.
| LW | TNGX | |
|---|---|---|
Market Cap | $7.16B | $3.75B |
Volume | 2,766,229 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $32.90 |
52-Week Low | $38.48 | $7.50 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $10.95B | $2.77B |
Dividend Yield | 2.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $53.02, up 5.66% today, near the consensus price target of $53.71. The stock shows bullish technical signals with strong moving averages and recent earnings beats. Revenue reached $6.45B in 2025, though net income margin compressed to 3.85%. The company maintains a solid balance sheet with $70.70M cash and ongoing dividend payments of $0.38 per share.
Outlook remains mixed; analyst consensus leans Hold (63%) with potential upside to $58.00. Key risks include margin pressure from high debt and volatile earnings. Positive sentiment from cost-saving initiatives supports recovery, but investor confidence hinges on sustained profitability improvements amid competitive pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
